ArticleBritish journal of cancer2019

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

César Serrano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.